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a b s t r a c t
Duck Tembusu virus (DTMUV) is a newly emerging pathogenic ﬂavivirus that is causing massive economic loss
in the Chinese duck industry. To obtain a live vaccine candidate against the disease, the DTMUV isolate FX2010
was passaged serially in chicken embryo ﬁbroblasts (CEFs). Characterization of FX2010-180P revealed that it
was unable to replicate efﬁciently in chicken embryonated eggs, nor intranasally infect mice or shelducks at
high doses of 5.5 log10 tissue culture infectious doses (TCID50). FX2010-180P did not induce clinical symptoms,
or pathological lesions in ducks at a dose of 5.5 log10 TCID50. The attenuation of FX2010-180P was due to 19
amino acid changes and 15 synonymousmutations. Importantly, FX2010-180P elicited good immune responses
in ducks inoculated at low doses (3.5 log10 TCID50) and provided complete protection against challenge with
a virulent strain. These results indicate that FX2010-180P is a promising candidate live vaccine for prevention
of duck Tembusu viral disease.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Since April 2010, outbreaks of infectious disease in ducks that
are characterized by retarded growth and rapid egg drop have
spread widely in China. The causative agent has been identiﬁed as
duck Tembusu virus (DTMUV), a newly emerged duck virus that
belongs to the genus Flavivirus in Flaviviridea family (P. Yan et al.,
2011). The important mosquito-borne pathogens within this virus
family include Japanese encephalitis virus (JEV), dengue virus
(DENV), West Nile virus (WNV), and yellow fever virus (YFV).
The infectious diseases caused by mosquito-borne ﬂaviviruses
generally occur in summer and autumn in temperate areas.
However, the disease caused by DTMUV is characterized by out-
breaks throughout the year. The outbreaks persist even when
ambient temperatures are lower than freezing, conditions under
which no insects are active in northern China (P. Yan et al., 2011).
This is a signiﬁcant difference compared with the diseases caused
by other insect-borne ﬂaviviruses. The duck Tembusu viral disease
caused by DTMUV has caused massive economic loss in the
Chinese duck industry. However, no vaccine is currently available
for prevention of the disease.
Serial passage of parental ﬂaviviruses in cell culture is often used
for developing live attenuated vaccine candidates. Yellow fever 17D
strain, a classic live-attenuated vaccine, has been obtained by passing
the parental virus through modiﬁed chicken embryo tissues (Barrett
and Teuwen, 2009). Similarly, the SA 14-14-2 strain of the Japanese
encephalitis (JE) vaccine was derived from serial passage of the SA14
virus in primary hamster kidney (PHK) cell culture (Yu, 2010).
A DTMUV FX2010 strain isolated previously from sick shelducks
with rapid egg drop caused systemic infection and lesions in ducks
(P. Yan et al., 2011). Here, we report the derivation of FX2010-180P, a
strain that emerged from FX2010 after 180 passages and was
avirulent in 3- to 5-week-old ducks. However, FX2010-180P induced
vigorous immune responses and protected the ducks against the
virulent FX2010 strain. The virulence, genetic characteristics, and
immunogenicity in ducks of FX2010 derivatives obtained at different
passages are also discussed.
Results
Mortality and replication of DTMUVs in chicken embryos
The virulence of a dose of 5.0 log10 TCID50 of viruses was evaluated
in 8-day-old SPF chicken embryonated eggs. All the embryos in these
eggs inoculated with FX2010 died within 36–96 h.p.i, and the survival
time was of 56.4720.4 h (Fig. 1). Viral virulence in the SPF chicken
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embryonated eggs decreased gradually as passage number increased.
The survival time of egg embryos inoculated with FX2010-60P,
FX2010-80P, FX2010-100P, FX2010-130P, and FX2010-145P increased
to 93.6718.6, 99.6722.7 h, 106.8722.9 h, 112.8727.8 h, and
109.2723.6 h, respectively (Fig. 1). Both mortality and infection
rate associated with eggs inoculated with FX2010, FX2010-60P,
FX2010-80P, FX2010-100P, FX2010-130P, and FX2010-145P were
100%. While the mortality rates of eggs inoculated with FX2010-
168P and FX2010-180P decreased to 60% and 20% within 168 h.p.i
(Fig. 1), the infection rates in these cases were 70% and 20% when
the allantoic ﬂuid was tested using real-time PCR, respectively.
The average DTMUV RNA copy number in allantoic ﬂuid of
FX2010-infected eggs reached 5.21 log10 copies/μl, while in the
eggs infected with FX2010-60P, FX2010-80P, FX2010-100P,
FX2010-130P, FX2010-145P, FX2010-168P, and FX2010-180P, the
average DTMUV RNA copy number ranged from 3.70 to 4.03 log10 -
copies/μl (Fig. 1). The DTMUV RNA copy number in FX2010-
infected eggs was signiﬁcantly higher than that of eggs infected
with serially passaged viral strains (Fig. 1; Po0.01, Student0s
t-test). There were no signiﬁcant differences (Fig. 1; P40.05,
Student0s t-test) in the DTMUV RNA copy number for infected
eggs for virus strains with different passage numbers, although the
mortality and infectivity associated with both FX2010-168P and
FX2010-180P was lower than that for the other strains.
Replication of serially passaged viruses in mice
To evaluate the infectivities of the different passage viruses in
mice, 5.0 log10 TCID50 of viruses were inoculated i.c. or i.n. (30- or
50-μl volumes) into 4-week-old SPF Balb/c mice. At 4 d.p.i., the
average RNA copy number of FX2010 in the lung supernatant of
the mice inoculated i.n. was 3.68 log10 copies/μl. However, the
DTMUV RNAs in mouse lungs decreased signiﬁcantly as passage
number increased, and only very low DTMUV RNA copy numbers
were observed in mice inoculated with FX2010-60P, FX2010-80P,
and FX2010-100P. There was a statistically signiﬁcant difference in
copy number between the FX2010-infected group and the pas-
saged virus-infected groups (Fig. 2a; Po0.01, Student0s t-test).
No DTMUV RNAs were detected in the lungs of mice inoculated
with FX2010-130P, FX2010-145P, FX2010-168P, or FX2010-180P
(Fig. 2a), suggesting that the virus lost its ability to infect lung
tissue after 130 passages. In all the brains of mice inoculated
i.c. with virus, the viral RNAs could be detected by real-time PCR.
The average RNA copy number in the brains of mice inoculated
with FX2010 was as high as 5.64 log10 copies/μl, which was
signiﬁcantly higher than that in brains from mice inoculated with
passaged viruses (Fig. 2b; Po0.01, Student0s t-test). The average
RNA copy number in the brains of mice inoculated with FX2010-
180P was signiﬁcantly lower than that observed with the virus
obtained from earlier passages (Fig. 2b; Po0.01, Student0s t-test).
To evaluate the neurovirulence of viruses in newborn mice,
3-day-old SPF Balb/c mice were inoculated i.c. with 5.0 log10
TCID50 of FX2010 or FX2010-180P. At both 4 and 6 d.p.i., the DTMUV
RNA copies in the brains of mice inoculated with FX2010-180P
were signiﬁcantly lower than in the brains of mice inoculated with
FX2010 (Fig. 2c; Po0.01, Student0s t-test).
To test the stability of FX2010-180P in mouse brains, the whole
genome of the FX2010-180P was ampliﬁed from brains of mice
euthanized on day 6 post-infection by reverse transcription poly-
merase chain reaction (RT-PCR). The PCR product was sequenced,
but no mutation was found, suggesting that FX2010-180P was
stable in the brain of mice in one passage.
Pathogenicity and infectivity of virus in ducks inoculated intranasally
Clinical symptoms, including lethargy, anorexia, and greenish
diarrhea were observed in the ducks inoculated i.n. with FX2010
at 3–4 d.p.i. Mild anorexia and occasional greenish diarrhea were
observed in ducks infected with FX2010-60P and FX2010-80P.
None of the ducks inoculated with FX2010-100P or FX2010-130P
showed any obvious clinical symptoms. Infection with FX2010
caused grossly swollen spleens and mildly swollen kidneys, whereas
FX2010-60P, FX2010-80P, and FX2010-100P caused gross to mild
spleen swelling. Importantly, infection with FX2010-130P did not
cause any visible pathogenic changes in ducks under these conditions.
In order to detect viral replication, the spleen, lung, kidney, and
brain of the i.n. inoculated ducks were collected at 4 d.p.i, homo-
genized, titrated on DF-1 cells, or tested by real-time PCR for
DTMUV-speciﬁc RNA. A high titer of viruses and DTMUV-speciﬁc
RNA was detected in the spleen, lung, kidney, and brain of the
ducks inoculated with 3.5 log10 TCID50 of FX2010 (Table 2). Viruses
from passages later than FX2010-60P were not able to replicate
in the brain under these conditions. However, the replication
of 130th passage viruses was not detected in any of the organs
tested, and the seroconversion testing using blocking ELISA in the
remaining ducks from each group revealed that only one-third
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Fig. 1. Mortality and replication of DTMUVs in chicken embryos. Ten 8-day-old SPF chicken embryonated eggs were inoculated intra-allantoically with different passage
viruses at a dose of 5.0 log10 TCID50. The eggs were incubated at 37 1C and checked daily. The survival times of the inoculated eggs were recorded. Viral infection in chicken
embryonated eggs was tested by real-time PCR methods, and embryo samples with a Ct value lower than 35 were considered DTMUV RNA- positive. The DTMUV RNA in the
allantoic ﬂuid of the positive eggs was quantiﬁed using the same real-time PCR methods. Statistically signiﬁcant differences between FX2010-infected eggs and the passage
virus-infected eggs are marked with asterisks (Po0.01).
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of the FX2010-130P inoculated animals underwent conversion at
14 d.p.i.
Pathogenicity and infectivity of virus in ducks inoculated i.m.
The clinical symptoms in ducks inoculated i.m. and those
inoculated i.n. with FX2010 were similar, and were observed at
3–4 d.p.i. None of the other viral strains induced obvious clinical
symptoms. Compared with FX2010, which caused grossly swollen
spleens and mild swollen kidneys, FX2010-130P and FX2010-145P
caused gross-to-mild spleen swelling at 4 d.p.i. In contrast, neither
FX2010-168P nor FX2010-180P induced any visible pathogenic
changes under these conditions.
High viral titers and DTMUV-speciﬁc RNA were detectable in
the spleen, lung, kidney, and brain of the 3 ducks inoculated with
FX2010 (Table 2). However, virus and DTMUV-speciﬁc RNA was
only detectable in the spleens of ducks inoculated with FX2010-
180P. Seroconversion was veriﬁed with blocking ELISA in all the
remaining ducks inoculated with serially passaged viral strains.
Pathogenicity and infectivity of virus in ducklings inoculated i.m.
To evaluate the pathogenicity and infectivity of viruses in
ducklings, 5-day-old ducks were inoculated i.m. with 3.5 log10 T-
CID50 of FX2010 or 5.5 log10 TCID50 of FX2010-180P. The clinical
symptoms, including lethargy, anorexia, and greenish diarrhea
were also observed in ducklings inoculated with FX2010 at 3–4 d.
p.i. None of the obvious clinical symptoms were induced by
FX2010-180P. Compared with FX2010, which also caused grossly
swollen spleens and mildly swollen kidneys, FX2010-180P did not
induce any visible pathogenic changes in ducklings. The viral titers
in different organs of ducklings were very similar with which in
8-week-old ducks, inoculated either with FX2010 or FX2010-180P
(Table 2).
Viral RNA copy numbers in the sera of ducks inoculated with FX2010
or FX2010-180P
To compare the viremia caused by FX2010 and FX2010-180P,
ﬁve 3- to 5-week-old ducks each were inoculated either i.n. or i.m.
with 3.5 log10 TCID50 of FX2010 or 5.5 log10 TCID50 of FX2010-180P.
The highest serum viral RNA copy numbers ranged from 5.16 to
5.81 log10 copies/μl and were most frequently observed in ducks
inoculated i.n. with FX2010 on day 2 post-inoculation. Titer values
then decreased at 4 d.p.i. and disappeared after 5 d.p.i. (Table 3).
In ducks inoculated i.m. with FX2010, the highest serum viral
RNA copy numbers ranged from 4.36 to 5.89 log10 copies/μl and
appeared 1 day earlier than in intranasally-inoculated ducks. Titers
then decreased at 3 d.p.i. and disappeared 4 d.p.i. Strikingly, no
FX2010-180P viral RNA was detected in the sera of ducks inocu-
lated by either route over the 14-day period post-inoculation
(Table 3).
Antibody responses of ducks inoculated with FX2010 or FX2010-180P
All ducks inoculated i.m. with FX2010 were seroconverted at
3 d.p.i. Three of ﬁve ducks inoculated i.n. with FX2010 were
seroconverted at 3 d.p.i, with the remaining animals undergoing
seroconversion by 4 d.p.i. However, none of the ducks inoculated
i.n. with FX2010-180P showed seroconversion at 14 d.p.i. (Fig. 3a).
Two of ﬁve ducks inoculated i.m. with FX2010-180P were sero-
converted at 4 d.p.i and the remaining ducks seroconverted at 6 d.
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Fig. 2. In vivo replication of viruses isolated from different passages. Groups of three 4-week-old female or six 3-day-old newborn BALB/c mice were lightly anesthetized
using carbon dioxide (CO2). The 4-week-old mice were treated intranasally (i.n.) with 50 μl or inoculated intracerebrally (i.c.) with 30 μl containing 5.0 log10 TCID50 of virus,
and newborn mice were inoculated i.c. with the same amount of virus. On day 4 post-inoculation, three mice from each group were euthanized and the lungs (a) of those
inoculated i.n. and the brains of those 4-week-old (b) and newborn mice (c) inoculated i.c. were collected. On day 6 post-inoculation, the remaining newborn mice (c) were
euthanized and the brains were collected. The collected organs were homogenized in PBS to yield 1:1 (ml/organ) tissue homogenates, and clariﬁed by centrifugation at
12,000 rpm for 10 min at 4 1C. The supernatants of tissue homogenates were used for DTMUV RNA quantiﬁcation. Statistically signiﬁcant differences between the FX2010-
infected group and the passage virus-infected groups inoculated both i.n. and i.c. and the differences between the group inoculated i.c with FX2010-180P and the group
inoculated i.c with other passage viruses are marked with asterisks and connecting lines (Po0.01).
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p.i. Compared with the results for FX2010, the antibody responses
induced by FX2010-180P were delayed by approximately 2–3 days,
and the PI values of antibodies were 20% lower than those induced
by FX2010 (Fig. 3b).
Sequence analysis
Viral virulence gradually decreased as passage number increased.
To explore the molecular basis underlying the attenuation of infectiv-
ity, the complete viral genomes of all viruses in this study were
sequenced. Compared with FX2010, no virus RNA was detectable in
the brains of ducks, and only very low amounts of RNA were found in
the lungs of partial mice infected with FX2010-60P. The attenuation
might be associated with 5 amino acid substitutions and 2 synon-
ymous nucleotide substitutions. Three amino acid substitutions
(D120N, V132A, and M349K) were in the E protein, 1 amino acid
substitution (V262A) was within the NS1 protein and the other (T322I)
was in NS3 (Table 4). Two synonymous nucleotide substitutions were
at positions 433 and 3368 in the viral genome. Furthermore, there was
a mixture of original and mutated nucleotides at 4 positions (1420,
4865, 6956, and 8105) in the viral genome, indicative of positions that
are actively undergoing selection during passaging. The mixed nucleo-
tides at 3 positions (4865, 6956, and 8105) did not change amino
acids, and only these at the positions 1420 resulted in mixed amino
acids (Y and F) at the position 155 of E protein.
Compared with FX2010-60P, the pathogenicity of FX2010-80P
and FX2010-100P was not signiﬁcantly reduced. Additional mixed
nucleotides were found at position 1426, resulting in mixed amino
acids (A and V) at the position 157 of E protein, in the genome of
FX2010-80P, and at position 1222, resulting in mixed amino acids (E
and G) at the position 89 of E protein, in the genome of FX2010-100P.
Consistent with its reduced virulence compared to viruses
isolated at earlier passages, more nucleotide substitutions were
evident in the genome of FX2010-130P. A comparison with
FX2010-60P, FX2010-80P, and FX2010-100P revealed that amino
acid E-155 in FX2010-130P was ﬁxed, as it had changed from Y to
F, and additional mixed amino acids were found at 5 positions in
M (106), NS1 (205), NS4A (110), and NS4B (50 and 112) proteins.
With regard to synonymous nucleotide changes, 2 substitutions
were ﬁxed, as they had changed from A to T at position 4865 and
form C to T at position 6956, and additional mixed bases were
found at 4 positions (1992, 2060, 8105 and 8264) in the genome of
FX2010-130P. Two amino acid substitutions, E89G and A157V,
were ﬁxed in the E protein of FX2010-145P, when compared with
FX2010-130P. No mixed nucleotides at single position were found
in the sequence of FX2010-168P. The mixed amino acid at 5 posi-
tions (M-106, NS1-205, NS4A-110, NS4B-50, and NS4B-112) in
early passages were ﬁxed in FX2010-168P, and 2 additional amino
changes E-R166K and NS5-V793A were found in FX2010-168P.
The virulence of FX2010-180P was attenuated dramatically in
mice and in chicken embryonated eggs, but was not signiﬁcantly
different to FX2010-168P with respect to pathogenicity in ducks.
Four amino acids (E-D37N, NS1-R192G, NS4AF54L, and NS5-
R273G) and 2 synonymous nucleotides in the stop codon and 30
noncoding region (NCR) were different between FX2010-168P and
FX2010-180P. Compared with the results for FX2010, a total of 34
nucleotide changes were found in the entire genome of FX2010-
180P. Of these, 19 missense mutations resulted in 19 amino acid
changes. These included the following: one change in prM/M;
eight in E; three in NS1; one in NS3; two changes each in NS4A,
NS4B, and NS5 (Table 4); and 15 synonymous changes (Table 5).
In addition, 2 synonymous changes were found in the 30-NCR.
Immunoprotection in ducks vaccinated with FX2010-180P
To evaluate the immunogenicity of FX2010-180P, ducks were
vaccinated i.m. with a 3.5 log10 TCID50 dose of the virus. The antibody
titers (PI value) of immunized ducks ranged from 48.2% to 64.5% at
2 w.p.i., 54.9% to 64.3% at 4 w.p.i., 47.0% to 62.0% at 8 w.p.i., and 45.0%
to 61.8% at 12 w.p.i., while that of control ducks were lower than
12.9% (Fig. 4a). After challenge with FX2010 at 2 or 12 w.p.i., the
control ducks had typical clinic symptoms as described previously.
However, none of the ducks vaccinated with FX2010-180P showed
any obvious clinical symptoms. Three ducks in each group were
euthanized and dissected at day 4 post challenge. The ducks in
control groups showed grossly swollen spleens, ruptured ovarian
follicles, and vitelline peritonitis (Fig. 4c). In contrast, the ducks
vaccinated with FX2010-180P had normal spleens and ovaries
(Fig. 4d). Whereas virus was isolated from the spleens, lungs,
kidneys, ovaries, and brains of all control ducks (Fig. 4b), it was
absent from vaccinated animals, suggesting that FX2010-180P affords
complete protection against FX2010 challenge at 2 and 12 w.p.i.
Discussion
The newly emerged duck Tembusu viral disease caused by
DTMUV had resulted in a huge economic loss to the Chinese duck
industry since 2010. In addition to ducks and geese, DTMUV can
infect other avian species, including chicken and house sparrows
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Fig. 3. Antibody responses in ducks inoculated with FX2010 or FX2010-180P. To compare the immune responses caused by FX2010 and FX2010-180P, groups of ﬁve 3- to
5-week-old SPF shelducks each were inoculated with 3.5 log10 TCID50 of FX2010 or 5.5 log10 TCID50 of FX2010-180P through i.n. (a) and i.m. (b) routes, respectively.
Two groups of 5 control shelducks were inoculated i.m. or i.n. with DMEM containing 2% FBS. Sera of all ducks were collected daily from 1 to 7 d.p.i. and at 10 and 14 d.p.i.
for antibody titration using the blocking ELISA method. The serum was considered DTMUV -positive when the PI value was Z18.4%.
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(Huang et al., 2012; Liu et al., 2012; Tang et al., 2012; P. Yan et al., 2011).
As a member of the Flaviviridae, DTMUV also poses a potential health
threat to mammals, including humans (S. Li et al., 2013; Liu et al.,
2013; Tang et al., 2013). To date, DTMUV is widespread in China, but
no effective measures are taken to prevent the disease.
Formalin-inactivated whole-virion vaccines produced in mouse
brain tissue or cell culture have been successfully developed for
other ﬂaviviruses, including those causing Japanese encephalitis
(McArthur and Holbrook, 2013), tick-borne encephalitis, louping
ill, and Kyasanur Forest disease (Monath, 2001). For preparation of
an inactivated vaccine, the virus must replicate to high titer, in
order to provide sufﬁcient antigenic mass. However, DTMUV does
not reach very high titers in cell culture during replication, which
has thwarted the development of inactivated vaccine against this
virus. To work around this issue, two doses of inactivated vaccine
have instead been employed in order to stimulate a signiﬁcant
immune response (Hoke et al., 1988). However, the higher prices
of inactivated ﬂavivirus vaccines (Hennessy et al., 1996) limit the
utility of this approach in animals, and in particular in poultry.
Live attenuated virus vaccines against ﬂaviviruses are widely
used. The most successful live attenuated virus vaccine is that
against yellow fever (YF). The 17D strain was developed in 1936 by
serial passaging and has been used in over 400 million persons,
with an excellent record of safety and efﬁcacy (Monath, 1999).
A single dose induces neutralizing antibodies in nearly 100% of
vaccinated individuals. Immunity is probably lifelong, although
revaccination is recommended every 10 years (Monath et al.,
2002). In 1988, an inexpensive live-attenuated vaccine against JE
(SA14-14-2) was ﬁrst licensed in China. SA14-14-2 demonstrated
an excellent safety proﬁle, effectiveness (88–96%), and efﬁcacy in
large-scale trials (involving 4200,000 children) (Halstead and
Thomas, 2010; Hennessy et al., 1996; Kumar et al., 2009; Liu et al.,
1997). More than 300 million doses have been produced and
administered to 4120 million children. Recently, the vaccine has
been licensed for use, and millions of doses have been adminis-
tered in Nepal, India, Sri Lanka, and South Korea (Halstead and
Thomas, 2010; Solomon, 2006). Preventive vaccine strategies
based on the construction of chimeric viruses of these licensed
live attenuated vaccines are being developed against WNV, DENV,
and others (Monath, 2001). However, all these licensed vaccines
are indicated for use in mammalians (including humans), and
there is no evidence to demonstrate the efﬁcacy of the backbone of
these vaccines in avian species. In this study, we developed an
attenuated vaccine candidate (FX2010-180P) against DTMUV by
serial passage of FX2010 in CEF cells. We believe this is the ﬁrst
report of an attenuated vaccine candidate against avian ﬂavi-
viruses. FX2010-180P could not i.n. infect ducks, nor replicate in
the lungs of i.n. infected mice, indicating that its horizontal
transmission in natural avian and artiﬁcial mammalian hosts was
eliminated by serial passaging. Moreover, the limited replication of
FX2010-180P in embryonated eggs and its low lethality to egg
embryos indicate its low virulence in vivo. Although FX2010-180P
stimulated a robust protective immune response in ducks, the viral
replication was limited strictly to the spleen. Similar to SA14-14-2
(Hase et al., 1993), the titers of FX2010-180P in the brains of mice
inoculated i.c. were still low at 4 d.p.i., suggesting that the vaccine
poses a low safety risk to mammals.
Many reports have shown that virus adaptation to cell lines
during passaging resulted in reduced virulence in vivo(Barrett and
Teuwen, 2009; Yu, 2010). Additionally, the host-speciﬁc adaption
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Fig. 4. Vaccination with FX2010-180P completely protects ducks against FX2010 challenge. To evaluate the immunogenicity of FX2010-180P, twenty 18-week-old shelducks
were vaccinated (i.m.) at a dose of 3.5 log10 TCID50. Twenty control shelducks were inoculated (i.m.) with PBS. The serum samples were collected for antibody titer testing
using blocking ELISA at 2, 4, 8 and 12 w.p.i (a). At 2 and 12 w.p.i, ducks were challenged i.m. with 3.5 log10 TCID50 of FX2010. Samples from the spleen, lung, kidney, brain, and
ovary were collected for virus titration, and high virus titers were detected from all organs of control ducks (b). The ducks in control groups showed grossly ruptured ovarian
follicles and vitelline peritonitis (c). In contrast, the ducks vaccinated with FX2010-180P had ovarian tissue with a normal appearance (d).
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and pathogenicity of ﬂavivirus may be associated with genetic
modiﬁcations in the 50-NCR, preM/M, E, NS1, NS2A, NS2B, NS3,
NS4A, NS4B, NS5, and 30-NCR of the virus (Butrapet et al., 2000;
Chiou and Chen, 2001; Ciota et al., 2007; Engel et al., 2010;
Holzmann et al., 1990, 1997; Mandl et al., 2000; Mitzel et al.,
2008; Puig-Basagoiti et al., 2007; Ruzek et al., 2008; Wicker et al.,
2012, 2006; Yamshchikov et al., 2004; Yoshii et al., 2010; Yu et al.,
2008; Zhang et al., 2006; Zhao et al., 2005). In this study, we
indeed found a number of mutations associated with passaging of
the virus in cell culture. Of these, those that affect the E protein
may play a more important role in the host-speciﬁc adaption and
attenuation of virus, since this protein mediates the essential
functions of attachment to, and fusion with, host cell membranes
(Rey et al., 1995). Mutations E-89 (Glu-Gly) and E-120 (Asp-
Asn) are located in domain II, which contains the fusion peptide
and has the ability to bind target membranes. Mutations near this
region change the fusion properties of the E protein in cell culture
and have been associated with alterations in neurovirulence. An
amino acid change in domain II resulted in a reduced neuroinva-
siveness of tick-borne encephalitis virus (TBEV) and WNV (Goto
et al., 2003; Zhang et al., 2006). In particular, mutation E-120
(Asp-Asn) lies near to the fusion loop and hence may contribute
to reduced neuroinvasiveness (Zhang et al., 2006). In addition, this
mutation introduces a potential glycosylation site (DCT-NCT)
that might affect virulence, since the envelope protein glycosyla-
tion status is reported to inﬂuence the mouse neuroinvasion
capacity of WNV (Beasley et al., 2005). The mutations E-312
(Val-Ala) and E-349 (Met-Lys) are located within the
receptor-binding domain III, a region in which mutations that
attenuate neurovirulence and neuroinvasiveness of ﬂaviviruses
have been identiﬁed (Holzmann et al., 1990, 1997; Jiang et al.,
1993; Mandl et al., 2000). Mutations E-37 (Tyr-Phe), E-155
(Tyr-Phe), E-157 (Ala-Val) and E-166 (Arg-Lys) are located in
domain I, another region that is a hotspot for attenuating muta-
tions (Jiang et al., 1993).
In addition, the M proteins may also be determinants of host-
speciﬁc replication of ﬂaviviruses (Mitzel et al., 2008). A mutation
in the M protein of ChimeriVax-JE led to a signiﬁcant change in the
susceptibility of the virus to changes in pH and to accelerated
growth kinetics (Maier et al., 2007). Structural studies of the M
and E proteins suggested that the ﬁrst 20 residues of M interact
with the ij loop in domain II of the E protein (Zhang et al., 2003).
The prM-106 (Ala-Val) mutation is located in a region of M
required for modulation of E protein function during early events
of infection such as membrane fusion (Maier et al., 2007). This
suggests that the prM-106 mutation might modulate membrane
fusion in a host-speciﬁc manner. On the other hand, the attenua-
tion of ﬂaviviruses during serials passaging in cells is associated
with frequent non-conservative changes in non-structural pro-
teins, such as NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5
(Butrapet et al., 2000; Chiou and Chen, 2001; Ciota et al., 2007;
Engel et al., 2010; Puig-Basagoiti et al., 2007; Ruzek et al., 2008;
Wicker et al., 2012, 2006; Yamshchikov et al., 2004; Yoshii et al.,
2010; Yu et al., 2008). In this study, 10 mutations were found in
non-structural proteins including NS1, NS3, NS4A, NS4B, and NS5
in the FX2010-180P strain. Most of these mutations arose in high
passage variants, and their appearance coincided with the decline
in replicative capacity in vivo (Tables 2 and 4). These mutations
might contribute to attenuation at the level of RNA replication or
other stages of the virus infectious cycle (Yamshchikov et al.,
2004). The mutations E-120, E-312, E-349, NS1-262, and NS3-322
ﬁrst arose in the FX2010-60P and might play important roles in
viral neurovirulence or neuroinvasiveness, as viruses with these
mutations were not detected in the brains of inoculated ducks.
On the other hand, the two nucleotide mutations in the 30-NCR
probably do not play important roles in viral attenuation since
they were not localized in the functionally important 30 stem-loop
structure (30-SL) common to many ﬂaviviruses (Markoff et al.,
2002; Yu and Markoff, 2005).
In short, we have successfully developed a live attenuated
vaccine candidate against duck Tembusu viral disease, in which
19 amino acid mutations in both structural and non-structural
proteins were found. Further work is required to map the
virulence determinants within these regions by reverse genetic
technology.
Materials and methods
Serial passage of the virus
DTMUV FX2010 isolated from sick shelducks in Shanghai was
used in this study (P. Yan et al., 2011). Primary CEFs prepared from
10-day-old Speciﬁc-pathogen-free (SPF) chicken eggs (Marival
Vital Laboratory Animal Technology Co., Ltd., Beijing, China) were
trypsinized and seeded in 75-cm2 ﬂasks with Dulbecco0s Modiﬁed
Eagle Medium (DMEM) containing 10% fetal bovine serum (FBS,
Biowest, South America), 2 mM glutamine, 100 U/ml penicillin,
and 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA) and were
maintained in a 5% CO2 humidiﬁed incubator at 37 1C. When the
cells reached 80–90% conﬂuence, they were washed with
phosphate-buffered saline (PBS) and infected with FX2010 at a
multiplicity of infection (MOI) between 0.1 and 0.5. After 1.5 h
incubation at 37 1C, the inoculum was removed. The monolayer
was washed 3 times with PBS to remove the unattached virus, and
10 ml of DMEM containing 2% (v/v) FBS was added to the culture
and incubated at 37 1C. Culture medium was harvested after 72 h
incubation or until 70% cytopathic effect (CPE) was evident. Cell
debris was removed by centrifugation, and the virus was stored at
70 1C. The same procedure was used to perform 172 additional
passages of the virus in CEF. FX2010-180P was developed by two
additional passages of FX2010-178P that was puriﬁed from the
173rd passage virus of FX2010 through 5 limited dilution titration
passages in CEF.
Animals
Three- to 4-week-old weanling SPF Balb/c mice and 3-day-old
newborn SPF Balb/c mice (Shanghai Slac Laboratory Animal Co.
Ltd., Shanghai, China) were used in mouse experiments. Shelducks
were hatched from SPF Shelduck eggs (Harbin Veterinary Research
Institute), housed in isolators for 3 days to 8 weeks, and used for
duck experiments. All animal experiments were approved by the
Animal Care and Use Committee of Shanghai Veterinary Research
Institute, Chinese Academy of Agricultural Sciences.
Infection of chicken embryos
To evaluate the mortality of the different passages in chicken
embryos, groups of ten 8-day-old SPF chicken embryonated eggs
were subjected to intra-allantoic injection with 100 μl of inoculum
containing 5.0 log10 TCID50 of FX2010, 60th passage virus (FX2010-
60P), 80th passage virus (FX2010-80P), 100th passage virus
(FX2010-100P), 130th passage virus (FX2010-130P), 145th passage
virus (FX2010-145P), 168th passage virus (FX2010-168P), and
180th passage virus (FX2010-180P). The eggs were incubated
continually at 37 1C and checked daily. The survival time of the
inoculated eggs was recorded. To verify viral infection in chicken
embryonated eggs, DTMUV-speciﬁc RNA in the supernatants of
the homogenated dead or alive embryos was evaluated by real-
time PCR (L. Yan et al., 2011). When the viral RNA copy number in
total allantoic ﬂuid of these eggs was 10-fold higher than that in
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the inoculated column, the embryos of these eggs were assumed
to be positive for DTMUV infection. Subsequently, DTMUV RNA in
the allantoic ﬂuid of the positive eggs was determined using real-
time PCR.
Mouse experiments
To evaluate the replication abilities of the different passages in
mammalian models, groups of three 4-week-old female BALB/c
mice were lightly anesthetized using carbon dioxide (CO2) and
inoculated intracerebrally (i.c.) with 30 μl or intranasally (i.n.) with
50 μl of 5.0 log10 TCID50 of each viral strain. Four days post-
inoculation (d.p.i.), the mice were euthanized and the brain and
lung tissues of mice inoculated via i.c. and i.n. routes were
collected, respectively. The tissues collected were homogenized
in PBS to yield 1:1 (ml/organ) tissue homogenates, and clariﬁed by
centrifugation at 12,000 rpm for 10 min at 4 1C. The supernatants
of tissue homogenates were used for DTMUV RNA quantiﬁcation.
To evaluate the neurovirulence of FX2010 and FX2010-180P,
each of six 3-day-old newborn mice was inoculated i.c. with 30 μl
of 5.0 log10 TCID50 of each viral strain. At 4 and 6 d.p.i., the brains
of mice were collected, homogenized and used for DTMUV RNA
quantiﬁcation as outlined above. Whole genome of the FX2010-
180P was ampliﬁed from brains of mice euthanized on day 6 post-
infection by reverse transcription polymerase chain reaction (RT-
PCR). The PCR product was sequenced to test the stability of
FX2010-180P in the brains of mice.
Duck experiments
To evaluate intranasal infectivities of different passages, groups
of six 8-week-old SPF shelducks were inoculated i.n. with 100 μl
of 3.5 log10 TCID50 of FX2010 or 5.5 log10 TCID50 of FX2010-60P,
FX2010-80P, FX2010-100P, and FX2010-130P, respectively. Six
control shelducks were inoculated with DMEM containing 2%
FBS. Ducks were observed twice a day for signs of disease. Three
ducks in each group were euthanized at 4 d.p.i, and samples from
the spleen, lung, kidney, and brain were collected for viral titration
and DTMUV RNA detection. The seroconversion of the remaining
3 ducks was tested at 14 d.p.i.
Studies of intramuscular activities were performed on 8-week-
old or 5-day-old SPF shelducks as outlined above, except that
the virus was injected intramuscularly. Other than 100 μl of
3.5 log10 TCID50 of FX2010, same volumes of 5.5 log10 TCID50 of
FX2010-130P, FX2010-145P, FX2010-168P, or FX2010-180P were
used to inoculate 8-week-old ducks. In addition, 100 μl of
3.5 log10 TCID50 of FX2010 or identical volumes of 5.5 log10 TCID50
of FX2010-180P were used to inoculate 5-day-old ducklings. Each
of the six 8-week-old or 5-day-old control shelducks were inocu-
lated intramuscularly with DMEM containing 2% FBS.
To track the growth and decline of viral RNA and antibody titers
in the sera, groups of ﬁve 3- to 5-week-old SPF shelducks each were
inoculated with 3.5 log10 TCID50 of FX2010, or 5.5 log10 TCID50
of FX2010-180P through either intranasal or intramuscular routes.
In each case, a control group of 5 shelducks inoculated with DMEM
containing 2% FBS was included. Sera of all the ducks were collected
daily from 1–7, and at 10 and 14 d.p.i. for viral RNA quantiﬁcation by
real-time PCR and antibody titration using the blocking ELISA method
(X. Li et al., 2013).
Viral titration
Organs were weighed and were homogenized in PBS contain-
ing 100 U/ml penicillin and 100 μg/ml streptomycin to yield 1:1
(ml/g) tissue homogenates. Tissue homogenates were clariﬁed by
centrifugation at 12,000 rpm for 10 min at 4 1C. The supernatants
were titrated in 96-well tissue culture plates containing the
spontaneously immortalized chicken embryo ﬁbroblast (DF-1)
cells (ATCC CRL-12203™). The virus titer for each organ was
determined by the method described by (Reed and Muench
(1938)) and expressed as log10 TCID50/g of tissue.
Blocking ELISA
To test for speciﬁc antibodies against DTMUV, a Blocking ELISA
method was used as described previously (X. Li et al., 2013).
Brieﬂy, ELISA plates were coated with approximately 3 μg/well
puriﬁed FX2010 in 0.1 M carbonate–bicarbonate buffer (pH 9.6)
and incubated overnight at 4 1C. Antigen-coated plates were
washed with PBS (pH 7.4) containing 0.05% Tween-20 (PBST),
and the nonspeciﬁc binding sites were blocked with 100 μl of
blocking buffer (PBS containing 5% skim milk) for 1 h at 37 1C.
Serum samples were initially diluted 10-fold with PBS, and then
further diluted through a series of 2-fold dilutions. Diluted serum
(100 μl) was added to each well and incubated for 1 h at 37 1C.
The wells were then washed 3 times with PBST and incubated
with mAb 1F5 (20 ) for 1 h at 37 1C. After the wells were rinsed
3 times with PBST, goat anti-mouse IgG (Sigma, USA) conjugated
to HRP was added, and the mixture was incubated at room
temperature (RT) for 1 h. After the wells were rinsed with PBST
3 times, 100 μl of 3,30,5,50-tetramethyl benzidine was added, and
the mixture was incubated at RT for 5 min. The reaction was then
stopped by adding 0.1 N sulfuric acid. The optical density (OD) was
measured at 450 nm, and the percent inhibition (PI) value was
determined using the formula: PI (%)¼[1(OD450 nm of test
serum/OD450 nm of negative control serum)]100%. The serum
was considered positive for DTMUV reactivity when the PI value
was Z18.4%. When the PI value was r12.6%, the serum was
considered negative. Intermediate PI values were considered as
“borderline positive”. Repeated analyses were performed on sera
with borderline PI values and were considered negative when the
re-tested values were less than 18.4%. The highest dilution of the
serum considered positive to DTMUV was determined as the
blocking ELISA titer for the anti-DTMUV antibody.
Real-time PCR
To quantify DTMUV RNA copy number in the samples, a pre-
viously described real-time RT-PCR assay with minor modiﬁcations
was employed (Yan et al., 2012; L. Yan et al., 2011). The tissues were
homogenized in PBS to yield 1:1 (ml/g of ducks tissue or ml/organ of
mouse tissue) tissue homogenates, and clariﬁed by centrifugation at
12,000 rpm for 10 min at 4 1C. The supernatants of tissue homoge-
nates were used for DTMUV RNA quantiﬁcation. Total RNA from 300 μl
of serum, the supernatant of tissue homogenate, or allantoic ﬂuid was
extracted using the RNeasy Plus Mini Kit (Qiagen) according to the
manufacturer0s instructions and was eluted in 20 μl of DEPC-treated
water. Reverse transcription was performed using AMV reverse
transcriptase (Takara Biotechnology, Dalian, China) with DTMUV-
speciﬁc primers (50-CGTATGGGTTGACTGTTATCA-30) in a ﬁnal volume
of 20 μl containing 5 μl of RNA solution, and then 1 μl of cDNA was
used in real-time RT-PCR. Brieﬂy, real-time PCR was performed on a
Mastercycler ep realplex system (Eppendorf, Hamburg, Germany)
using cycling conditions described previously (Yan et al., 2012; L. Yan
et al., 2011): 95 1C for 2 min, followed by 40 cycles each at 95 1C for
20 s and 54 1C for 1 min. The total reaction system contained 2.5 μl of
10 buffer, 2.5 μl of dNTP, 1 μl of each primer (10 mM of EF and ER),
0.6 μl of the probe (10 mM of EP), 1 μl of cDNA, 0.2 μl of Ex Taq Hot
Start, and 16.2 μl of sterile water. The RNA copies in the sample were
calculated by comparing 1 μl of cDNA with a standard sample.
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Genome sequencing
RNAs from different passages were extracted using the RNeasy
Plus Mini Kit. The 50 and 30 ends of the genomes were ampliﬁed
using 50 and 30 rapid ampliﬁcations of cDNA ends (RACE) methods.
Speciﬁc primers (Table 1) for DTMUV designed according to the
sequence of FX2010 were used for RT-PCR to generate nine
overlapping PCR products. The PCR products were puriﬁed using
the TIANquick Midi Puriﬁcation Kit (Tiangen, Beijing, China) and
then used for sequencing with ABI 3730 automated sequencers
(Applied Biosystems). Genome sequences were analyzed using
DNASTAR software.
Vaccination and challenge experiments
To evaluate the immunogenicity of FX2010-180P, twenty 18-
week-old shelducks were vaccinated i.m. with a 3.5 log10 TCID50
dose of virus. Twenty control shelducks were inoculated i.m. with
PBS. At 2 weeks post-inoculation (w.p.i.), 10 vaccinated and 10
Table 1
Primers used for full-genome sequencing of DTMUV.
Primer name Sequence (50–30) Map position
DTMUV-1F 50-AGAAGTTCATCTGTGTGAACTTATTCC-30 1–27
DTMUV-1R 50-CGGTACCATAATCCTCCATCTCAGC-30 1488–1512
DTMUV-2F 50-GGAAGCGAGCACCTACCACAAT-30 1397–1418
DTMUV-2R 50-CTGGGCACTCTTTAGTTTTTGGTCC-30 2868–2892
DTMUV-3F 50-GGAGAGCTCATGTACGGATGGAAGA-30 2784–2808
DTMUV-3R 50-TCTATCCCCACTATTCTGAGCCCTG-30 3994–4018
DTMUV-4F 50-CTTGGCGTTGCGTTAGCACTCAT-30 3834–3856
DTMUV-4R 50-CCTTTCAGTGCTTCCGCTATTTCAG-30 5278–5302
DTMUV-5F 50-AAAAGGCAACTAACAGTGCTGGACC-30 5145–5169
DTMUV-5R 50-GGCTGGGACTTCTGCTATCCATAAC-30 6725–6749
DTMUV-6F 50-TGACTACAGCTGAGAAAGGGAGCAG-30 6535–6559
DTMUV-6R 50-AGCAGTGTGTCAGATGGTTCAGTCG-30 8062–8086
DTMUV-7F 50-GTGAGAGGTTACACAAAAGGAGGGC-30 7953–7977
DTMUV-7R 50-CTTGCAGGTGCAGTTCTCTCTCTCT-30 8970–8994
DTMUV-8F 50-GAGAAGGTGAATAGTAACGCAGCCC-30 8862–8886
DTMUV-8R 50-TCCTTCCTGTGGGGACCCATGAGAC-30 10023–10047
DTMUV-9F 50-GTGGTTCCATGTCGAGACCAGGATG-30 9843–9867
DTMUV-9R 50-AGACTCTGTGTTCTACCACCACCAG-30 10967–10991
Table 2
Infectivity of different passages of FX2010 in ducks inoculated intranasally or intramuscularly.
Virus Age of ducks Inoculationa DTMUV RNA positive (virus titers [log10 TCID50/g])
Spleen Lung Kidney Brain
FX2010 8-week-old i.n. 3/3 (3.870.8b) 3/3 (4.171.2) 3/3 (3.371.1) 3/3 (2.270.5)
FX2010-60P 8-week-old i.n. 3/3 (4.871.1) 3/3 (/4.5/2.3/c) 3/3 (/2.8/2.3) 0/3 (d)
FX2010-80P 8-week-old i.n. 3/3 (4.371.4) 2/3 (/2.5/2.0) 2/3 (//2.5) 0/3 ()
FX2010-100P 8-week-old i.n. 3/3 ( /3.3/4.5) 1/3 (//2.0) 1/3 () 0/3 ()
FX2010-130P 8-week-old i.n. 0/3 () 0/3 () 0/3 () 0/3 ()
DMEM control 8-week-old i.n. 0/3 () 0/3 () 0/3 () 0/3 ()
FX2010 8-week-old i.m. 3/3 (3.970.9) 3/3 (4.270.9) 3/3 (3.171.3) 3/3 (2.470.4)
FX2010-130P 8-week-old i.m. 3/3 (4.471.7) 0/3 () 0/3 () 0/3 ()
FX2010-145P 8-week-old i.m. 3/3 (4.271.0) 0/3 () 0/3 () 0/3 ()
FX2010-168P 8-week-old i.m. 3/3 ( /3.0/3.3) 0/3 () 0/3 () 0/3 ()
FX2010-180P 8-week-old i.m. 3/3 ( /2.3/3.0) 0/3 () 0/3 () 0/3 ()
DMEM control 8-week-old i.m. 0/3 () 0/3 () 0/3 () 0/3 ()
FX2010 5-day-old i.m. 3/3 (3.770.6) 3/3 (4.070.7) 3/3 (3.170.8) 3/3 (2.370.5)
FX2010-180P 5-day-old i.m. 3/3 (2.170.5) 0/3 () 0/3 () 0/3 ()
DMEM control 5-day-old i.m. 0/3 () 0/3 () 0/3 () 0/3 ()
a Three of shelducks were each inoculated intranasally or intramuscularly with 3.5 log10 TCID50 of FX2010 or 5.5 log10 TCID50 of the strains derived by serial passaging.
Ducks were euthanized on day 4 post-inoculation and tissue samples were collected for viral titration and DTMUV RNA detection.
b Virus titers are shown as mean (log10 TCID50/g)7SD.
c Virus titers of individual organs are shown when organs from three ducks were not all virus-positive on DF-1 cells.
d None of the organs from three ducks were virus-positive on DF-1 cells.
Table 3
Viral RNA copies in the sera of ducks inoculated with FX2010 or FX2010-180P.
Virus Inoculationa Ducks 0 day 1 day DTMUV RNA copies (log10 copies/μl)
2 day 3 day 4 day 5 day 6 day 7 day 10 day 14 day
FX2010 i.n. 7026 b  5.16 4.90 1.70     
7027   5.81 3.21      
7028  – 5.33 5.69 3.01     
7029   5.21 3.53      
7030   5.32 5.08 1.37     
i.m. 7021  4.36 4.35       
7022  5.89 4.99 1.27      
7023  5.62 4.78 1.92      
7024  5.82 5.07 1.45      
7025  4.98 4.18       
FX2010-180P i.m. 7031–7035          
i.n. 7036–7040          
DMEM i.m. 7041–7045          
i.n. 7046–7050          
a Five 3- to 5-week-old ducks each were inoculated intranasally or intramuscularly with 3.5 log10 TCID50 of FX2010, or 5.5 log10 TCID50 of FX2010-180P. Sera were
collected 1–7, 10 and 14 days post-inoculation and used for DTMUV RNA detection by real-time PCR.
b  , Ct435 was considered negative.
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control ducks were challenged i.m. with 3.5 log10 TCID50 of FX2010
after their blood samples were collected from the wing (alar)
veins. Afterwards, the serum samples were used in antibody titer
testing by blocking ELISA. Ducks were observed twice a day for
signs of disease, and 3 ducks in each group were euthanized on
day 4 post-challenge. Samples from the spleen, lung, kidney, brain,
and ovary were collected for virus titration. The remaining ducks
were bled for sera which were then used in antibody titer testing
at 4, 8 and 12 w.p.i; the ducks were then challenged i.m. with
3.5 log10 TCID50 of FX2010 at 12 w.p.i. Studies of vaccine protection
against virulent DTMUV were performed as outlined above.
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